260: Comparison of Incidence of Systemic Viral Infection (SVI) and Invasive Fungal Infection (IFI) in Children Receiving Busulfan Based Reduced Intensity Allogeneic Stem Cell Transplant (RIAlloSCT) vs. Myeloablative AlloSCT (MA-AlloSCT) for Malignant and Non-Malignant Diseases

Abstract

We have previously demonstrated the safety and efficacy of RIAlloSCT in pediatric recipients (DelToro/Cairo et al, BMT, 2004; Bradley/Cairo et al, BMT, 2007). RIAlloSCT in adults is associated with a significant decrease in early bactermia (Junghanns et al, BBMT, 2002), but not in incidence of IFI or CMV (Fukuda et al, Blood 2003; Junghanns et al, Blood 2002). Date is lacking on incidence and timing of SVI and IFI in children undergoing RIAlloSCT. We compared the incidence of SVI and IFI in children receiving busulfan (BU)-based RIAlloSCT (group-A) vs.